See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Pacira BioSciences, Inc. (PCRX) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Pacira BioSciences, Inc. (PCRX) - free report >>
Image: Bigstock
Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Novartis AG (NVS - Free Report) entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti-PCSK9 antibody, LGT-209, as per a press release issued by the latter.
Although financial details of the agreement were kept under wraps, the deal does cover regulatory and commercial milestones.
Cyon licensed LGT-209 from Novartis and obtained the global rights of the compound for use in the prevention and treatment of sepsis and Systemic Inflammatory Response Syndrome (SIRS).
Results of a phase I study on LGT209 showed that the candidate was well tolerated and effective in lowering cholesterol. This mechanism of action is expected to prevent sepsis and improve outcomes in patients with or at risk of sepsis. As a result, Cyon plans to move the candidate into a phase II clinical program (initiation expected in first half of 2017). It is also planning to initiate a private VC round.
NOVARTIS AG-ADR Price
NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote
We note that Novartis is strategically reshaping its portfolio through acquisitions, licensing and partnerships.
Earlier this year, the company entered into a collaboration and license agreement with Xencor, Inc. (XNCR - Free Report) to bolster its immuno-oncology pipeline. Under the deal, Novartis obtained rights to develop four additional bispecific antibodies and to use other Xencor proprietary antibody engineering technology for up to 10 additional biotherapeutic programs across its portfolio.
Novartis currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Incorporated (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>